ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Christof Schmid
Hans H. Scheld
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wilhelm, M. J.
Right arrow Articles by Scheld, H. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilhelm, M. J.
Right arrow Articles by Scheld, H. H.

Ann Thorac Surg 1996;61:920-924
© 1996 The Society of Thoracic Surgeons


Original Articles: Cardiovascular

Cardiopulmonary Bypass in Patients With Heparin-Induced Thrombocytopenia Using Org 10172

Markus J. Wilhelm, MD, Christof Schmid, MD, Deniz Kececioglu, MD, Thomas Möllhoff, MD, Helmut Ostermann, MD, Hans H. Scheld, MD

Departments of Thoracic and Cardiovascular Surgery, Pediatric Cardiology, Anesthesiology, and Internal Medicine, University of Münster, Münster, Germany

Accepted for publication November 24, 1995.

Background. In patients with heparin-induced thrombocytopenia undergoing cardiac operations, anticoagulation with heparin should be avoided. The low-molecular-weight glycosaminoglycan Orgaran has been used as an alternative, but the overall experience is limited.

Methods. Two patients with heparin-induced thrombocytopenia underwent cardiopulmonary bypass using Orgaran for anticoagulation. A 30-year-old woman suffered from emboli to her brain through a secondary atrial septal defect, a 14-year-old boy from ischemia of his left leg due to recurrent embolism originating from the mitral valve. In both cases, cardiopulmonary bypass was performed in a routine manner, except for using low-dose Orgaran instead of heparin. Anticoagulation was monitored during cardiopulmonary bypass by measuring Orgaran plasma levels and activated clotting time.

Results. No thromboembolic or bleeding complications occurred during and after atrial septal defect repair and mitral valve replacement, respectively. In the former case, thrombotic material from the inferior vena cava was removed during hypothermic circulatory arrest within the same procedure. Activated clotting time did not correlate with plasma levels of Orgaran.

Conclusions. Orgaran might be a useful alternative for anticoagulation during extracorporeal circulation. Adequate dosages and measurement of plasma levels are recommended for its use in cardiopulmonary bypass.




This article has been cited by other articles:


Home page
ChestHome page
P. Monagle, E. Chalmers, A. Chan, G. deVeber, F. Kirkham, P. Massicotte, and A. D. Michelson
Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 887S - 968S.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
C. Bauer, Z. Vichova, P. Ffrench, C. Hercule, O. Jegaden, O. Bastien, and J.-J. Lehot
Extracorporeal Membrane Oxygenation with Danaparoid Sodium After Massive Pulmonary Embolism
Anesth. Analg., April 1, 2008; 106(4): 1101 - 1103.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
P. Monagle, A. Chan, P. Massicotte, E. Chalmers, and A. D. Michelson
Antithrombotic Therapy in Children*: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 645S - 687S.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. A. Cannon, J. Butterworth, R. D. Riley, and J. M. Hyland
Failure of argatroban anticoagulation during off-pump coronary artery bypass surgery
Ann. Thorac. Surg., February 1, 2004; 77(2): 711 - 713.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
W. E Dager and R. H White
Low-Molecular-Weight Heparin-Induced Thrombocytopenia in a Child
Ann. Pharmacother., February 1, 2004; 38(2): 247 - 250.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
Y. Sun, P. E. Greilich, S. I. O. Wilson, M. R. Jackson, and C. W. Whitten
The Use of Lepirudin for Anticoagulation in Patients with Heparin-Induced Thrombocytopenia During Major Vascular Surgery
Anesth. Analg., February 1, 2001; 92(2): 344 - 346.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
P. Monagle, A. D. Michelson, E. Bovill, and M. Andrew
Antithrombotic Therapy in Children
Chest, January 1, 2001; 119(1_suppl): 344S - 370S.
[Full Text] [PDF]


Home page
PerfusionHome page
P. Fernandes, R. Mayer, J. L MacDonald, A. G Cleland, and C. Hay-McKay
Use of danaparoid sodium (Orgaran(R)) as an alternative to heparin sodium during cardiopulmonary bypass: a clinical evaluation of six cases
Perfusion, December 1, 2000; 15(6): 531 - 539.
[Abstract] [PDF]


Home page
Ann. Thorac. Surg.Home page
F. Follis and C. A. Schmidt
Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis
Ann. Thorac. Surg., December 1, 2000; 70(6): 2173 - 2181.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
J. W. Frederiksen
Cardiopulmonary bypass in humans: bypassing unfractionated heparin
Ann. Thorac. Surg., October 1, 2000; 70(4): 1434 - 1443.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
R. E. Ariano, S. K. Bhattacharya, M. Moon, and L. G. Brownell
FAILURE OF DANAPAROID ANTICOAGULATION FOR CARDIOPULMONARY BYPASS
J. Thorac. Cardiovasc. Surg., January 1, 2000; 119(1): 167 - 168.
[Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
B. R. Saxon, M. D. Black, D. Edgell, D. Noel, and M. T. Leaker
Pediatric heparin-induced thrombocytopenia: management with Danaparoid (Orgaran)
Ann. Thorac. Surg., September 1, 1999; 68(3): 1076 - 1078.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
N. Gikakis, A. K. Rao, S. Miyamoto, J. H. Gorman III, M. M. H. Khan, H. L. Anderson, C. E. Hack, L. Sun, S. Niewiarowski, R. W. Colman, et al.
ENOXAPARIN SUPPRESSES THROMBIN FORMATION AND ACTIVITY DURING CARDIOPULMONARY BYPASS IN BABOONS
J. Thorac. Cardiovasc. Surg., December 1, 1998; 116(6): 1043 - 1051.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
T. B. Spanier, M. C. Oz, O. P. Minanov, R. Simantov, W. Kisiel, D. M. Stern, E. A. Rose, and A. M. Schmidt
Heparinless cardiopulmonary bypass with active-site blocked factorIXa: A preliminary study on the dog
J. Thorac. Cardiovasc. Surg., May 1, 1998; 115(5): 1179 - 1188.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. R. Jackson, C. A. Danby, and B. M. Alving
Heparinoid Anticoagulation and Topical Fibrin Sealant in Heparin-Induced Thrombocytopenia
Ann. Thorac. Surg., December 1, 1997; 64(6): 1815 - 1817.
[Abstract] [Full Text]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
D. Cummins and E. Hill
Heparin-Induced Thrombocytopenia
Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 349 - 365.
[Abstract] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
A. K. Ganjoo, M. G. Harloff, and W. D. Johnson
CARDIOPULMONARY BYPASS FOR HEPARIN-INDUCED THROMBOCYTOPENIA: MANAGEMENT WITH A HEPARIN-BONDED CIRCUIT AND ENOXAPARIN
J. Thorac. Cardiovasc. Surg., November 1, 1996; 112(5): 1390 - 1392.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1996 by The Society of Thoracic Surgeons.